Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 199

1.

The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer.

D'Ambrosio DJ, Hanlon AL, Al-Saleem T, Feigenberg SJ, Horwitz EM, Uzzo RG, Pollack A, Buyyounouski MK.

Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1082-7. Epub 2007 Jan 22.

PMID:
17241749
[PubMed - indexed for MEDLINE]
2.

Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.

Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24.

PMID:
14697416
[PubMed - indexed for MEDLINE]
3.

Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.

Kupelian PA, Buchsbaum JC, Patel C, Elshaikh M, Reddy CA, Zippe C, Klein EA.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):704-11.

PMID:
11849793
[PubMed - indexed for MEDLINE]
4.

Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.

Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. Epub 2005 May 31.

PMID:
15925452
[PubMed - indexed for MEDLINE]
5.

What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?

Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1003-10.

PMID:
15752879
[PubMed - indexed for MEDLINE]
6.

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.

PMID:
15050332
[PubMed - indexed for MEDLINE]
7.

A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.

Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A.

Am J Clin Oncol. 2006 Oct;29(5):458-62.

PMID:
17023779
[PubMed - indexed for MEDLINE]
8.

Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.

Wong WW, Schild SE, Vora SA, Halyard MY.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):24-9.

PMID:
15337536
[PubMed - indexed for MEDLINE]
9.
10.

Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10).

Kupelian PA, Buchsbaum JC, Reddy CA, Klein EA.

Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):621-5.

PMID:
11395228
[PubMed - indexed for MEDLINE]
11.

Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer.

Pinover WH, Hanlon AL, Horwitz EM, Hanks GE.

Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):649-54.

PMID:
10837947
[PubMed - indexed for MEDLINE]
12.

Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy.

Kestin LL, Goldstein NS, Vicini FA, Mitchell C, Gustafson GS, Stromberg JS, Chen PY, Martinez AA.

Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):107-18.

PMID:
12182980
[PubMed - indexed for MEDLINE]
13.

Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy.

Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A.

Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):59-66. Epub 2007 Oct 4.

PMID:
17919840
[PubMed - indexed for MEDLINE]
14.

Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?

D'Ambrosio DJ, Ruth K, Horwitz EM, Chen DY, Pollack A, Buyyounouski MK.

Urology. 2008 May;71(5):938-41. doi: 10.1016/j.urology.2007.09.049. Epub 2008 Feb 15.

PMID:
18279939
[PubMed - indexed for MEDLINE]
15.

Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.

Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1455-62. Epub 2005 Sep 19.

PMID:
16169682
[PubMed - indexed for MEDLINE]
16.

Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.

Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES.

J Clin Oncol. 2005 Feb 1;23(4):826-31.

PMID:
15681527
[PubMed - indexed for MEDLINE]
Free Article
17.

Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques.

Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE.

Cancer. 2001 Sep 1;92(5):1281-7.

PMID:
11571744
[PubMed - indexed for MEDLINE]
18.

Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?

Nguyen KH, Horwitz EM, Hanlon AL, Uzzo RG, Pollack A.

Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):377-83.

PMID:
12957248
[PubMed - indexed for MEDLINE]
19.

Analysis of biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer using dose-distribution variables and tumor control probability models.

Levegr√ľn S, Jackson A, Zelefsky MJ, Venkatraman ES, Skwarchuk MW, Schlegel W, Fuks Z, Leibel SA, Ling CC.

Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1245-60.

PMID:
10889378
[PubMed - indexed for MEDLINE]
20.

Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performance.

Williams SG, Buyyounouski MK, Pickles T, Kestin L, Martinez A, Hanlon AL, Duchesne GM.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1169-75. Epub 2007 Oct 29.

PMID:
17967518
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk